Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis

European Journal of NeurologyVolume 30, Issue 4 p. 1160-1161 LETTER TO THE EDITOR Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis Hai-Feng Li, Corresponding Author Hai-Feng Li [email protected] orcid.org/0000-0001-8541-279X Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China Correspondence Hai-Feng Li, Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China. Email: [email protected]Search for more papers by this authorFeng Gao, Feng Gao orcid.org/0000-0002-4961-3495 Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaSearch for more papers by this authorXiang-Jun Chen, Xiang-Jun Chen orcid.org/0000-0002-8108-9013 Department of Neurology, Huashan Hospital and Institute of Neurology, Fudan University, Shanghai, ChinaSearch for more papers by this author Hai-Feng Li, Corresponding Author Hai-Feng Li [email protected] orcid.org/0000-0001-8541-279X Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China Correspondence Hai-Feng Li, Department of Neurology, Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Beijing 100053, China. Email: [email protected]Search for more papers by this authorFeng Gao, Feng Gao orcid.org/0000-0002-4961-3495 Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaSearch for more papers by this authorXiang-Jun Chen, Xiang-Jun Chen orcid.org/0000-0002-8108-9013 Department of Neurology, Huashan Hospital and Institute of Neurology, Fudan University, Shanghai, ChinaSearch for more papers by this author First published: 24 January 2023 https://doi.org/10.1111/ene.15687Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Meisel A, Baggi F, Behin A, et al. The role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal. Eur J Neurol. 2023; 30(1): 266-282. doi:10.1111/ene.15565 10.1111/ene.15565 PubMedWeb of Science®Google Scholar 2Chen XJ, Qiao J, Xiao BG, Lu CZ. The significance of titin antibodies in myasthenia gravis—correlation with thymoma and severity of myasthenia gravis. J Neurol. 2004; 251(8): 1006-1011. 10.1007/s00415-004-0479-z PubMedWeb of Science®Google Scholar 3Liu JF, Wang WX, Xue J, et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial. 2010; 14(2): 153-160. 10.1111/j.1744-9987.2009.00751.x CASPubMedWeb of Science®Google Scholar 4Wang L, Wang S, Yang H, et al. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients. Brain Behav. 2021; 11(7):e02203. 10.1002/brb3.2203 CASPubMedWeb of Science®Google Scholar 5Jiang P, Li J, Li HY, et al. Minimal manifestation status indicates a stable state in myasthenia gravis: a quantitative study. Front Neurol. 2022; 13:880045. 10.3389/fneur.2022.880045 PubMedWeb of Science®Google Scholar Citing Literature Volume30, Issue4April 2023Pages 1160-1161 ReferencesRelatedInformation